Ascentage Pharma Group International (AAPG) Competitors $38.62 +1.86 (+5.06%) As of 07/16/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock AAPG vs. ITCI, GMAB, MRNA, RDY, VTRS, QGEN, ASND, VRNA, BBIO, and BPMCShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Its Competitors Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris QIAGEN Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations. Is ITCI or AAPG more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Ascentage Pharma Group International's return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Ascentage Pharma Group International N/A N/A N/A Do analysts rate ITCI or AAPG? Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Intra-Cellular Therapies' higher probable upside, analysts plainly believe Intra-Cellular Therapies is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, ITCI or AAPG? Ascentage Pharma Group International has higher revenue and earnings than Intra-Cellular Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Ascentage Pharma Group International$980.65M3.43-$55.54MN/AN/A Do insiders and institutionals believe in ITCI or AAPG? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer ITCI or AAPG? In the previous week, Ascentage Pharma Group International had 11 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 12 mentions for Ascentage Pharma Group International and 1 mentions for Intra-Cellular Therapies. Ascentage Pharma Group International's average media sentiment score of 0.49 beat Intra-Cellular Therapies' score of 0.29 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascentage Pharma Group International 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAscentage Pharma Group International beats Intra-Cellular Therapies on 8 of the 13 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.20B$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E RatioN/A20.3628.1219.69Price / Sales3.43298.74439.46100.25Price / CashN/A42.3835.5357.53Price / Book80.467.768.235.67Net Income-$55.54M-$55.11M$3.23B$257.51M7 Day Performance-5.20%0.19%-0.52%-0.16%1 Month Performance22.06%10.80%6.71%9.89%1 Year PerformanceN/A-0.68%27.10%15.08% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$38.62+5.1%N/AN/A$3.20B$980.65M0.00600ITCIIntra-Cellular Therapies0.9132 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9224 of 5 stars$21.40-2.1%$37.80+76.6%-19.0%$14.02B$3.12B12.162,682Analyst RevisionMRNAModerna4.3464 of 5 stars$33.64-1.9%$46.61+38.6%-74.4%$13.26B$3.24B-3.855,800Analyst RevisionRDYDr. Reddy's Laboratories2.7592 of 5 stars$14.51-1.1%$16.95+16.8%-6.7%$12.25B$3.81B21.9827,811News CoverageVTRSViatris3.084 of 5 stars$9.12-1.4%$10.40+14.0%-20.2%$10.86B$14.74B-2.8832,000Positive NewsQGENQIAGEN3.6905 of 5 stars$48.13-0.9%$49.40+2.6%+16.7%$10.79B$1.98B120.675,765ASNDAscendis Pharma A/S3.7055 of 5 stars$174.96-0.9%$223.07+27.5%+24.6%$10.70B$368.70M-27.861,017Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2778 of 5 stars$104.830.0%$107.45+2.5%+370.5%$8.93B$42.28M-52.4230Analyst ForecastHigh Trading VolumeBBIOBridgeBio Pharma4.6331 of 5 stars$46.47+0.4%$60.21+29.6%+61.0%$8.79B$221.90M-13.16400Analyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.0941 of 5 stars$129.300.0%$128.25-0.8%+7.3%$8.35B$562.12M-52.35640Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives VRNA Alternatives BBIO Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
